Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis

被引：30

作者：

Cavaletti, G

Cavalletti, E

Crippa, L

Di Luccio, E

Oggioni, N

Mazzanti, B

Biagioli, T

Sala, F

Sala, V

Frigo, M

Rota, S

Tagliabue, E

Stanzani, L

Galbiati, S

Rigolio, R

Zoia, C

Tredici, G

Perseghin, P

Dassi, M

Riccio, P

Lolli, F

机构：

[1] AO Osped S Gerardo, Neurol Clin, Dept Neurol, I-20052 Monza, MI, Italy

[2] Univ Milano Bicocca, Dept Neurosci & Biomed Technol, Monza, Italy

[3] Cell Therapeut Inc Europe, Bresso, Italy

[4] Univ Florence, Dept Organ Chem, I-50121 Florence, Italy

[5] Univ Florence, Careggi Hosp, Dept Neurol Sci, I-50121 Florence, Italy

[6] AO Osped S Gerardo, Dept Immunohaematol, I-20052 Monza, MI, Italy

[7] Univ Basilicata, Dept Biochem, I-85100 Potenza, Italy

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2004年 / 151卷 / 1-2期

关键词：

experimental allergic encephalomyelitis; rat; pixantrone; mitoxantrone; pathology;

D O I：

10.1016/j.jneuroim.2004.02.008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Pixantrone is less cardiotoxic and is similarly effective to mitoxantrone (MTX) as an antineoplastic drug. In our study, pixantrone reduced the severity of acute and decreased the relapse rate of chronic relapsing experimental allergic encephalomyelitis (EAE) in rats. A marked and long-lasting decrease in CD3+, CD4+, CD8+ and CD45RA+ blood cells and reduced anti-MBP titers were observed with both pixantrone and MTX. In vitro mitogen- and antigen-induced T-cell proliferation tests of human and rodents cells evidenced that pixantrone was effective at concentrations which can be effectively obtained after i.v. administration in humans. Cardiotoxicity was present only in MTX-treated rats. The effectiveness and the favorable safety profile makes pixantrone a most promising immunosuppressant agent for clinical use in multiple sclerosis (MS). (C) 2004 Elsevier B.V. All rights reserved.

引用

页码：55 / 65

页数：11

共 21 条

[1]

ALDERTON PM, 1992, CANCER RES, V52, P194

[2] Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis [J].

Avasarala, JR ;

Cross, AH ;

Clifford, DB ;

Singer, BA ;

Siegel, BA ;

Abbey, EE .

MULTIPLE SCLEROSIS, 2003, 9 (01) :59-62

[3] BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity [J].

Beggiolin, G ;

Crippa, L ;

Menta, E ;

Manzotti, C ;

Cavalletti, E ;

Pezzoni, G ;

Torriani, D ;

Randisi, E ;

Cavagnoli, R ;

Sala, F ;

Giuliani, FC ;

Spinelli, S .

TUMORI, 2001, 87 (06) :407-416

[4] Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event [J].

Berger, T ;

Rubner, P ;

Schautzer, F ;

Egg, R ;

Ulmer, H ;

Mayringer, I ;

Dilitz, E ;

Deisenhammer, F ;

Reindl, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (02) :139-145

[5]

BERTAZZOLI C, 1979, CANCER TREAT REP, V63, P1877

[6] Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma [J].

Borchmann, P ;

Schnell, R ;

Knippertz, R ;

Staak, JO ;

Camboni, GM ;

Bernareggi, A ;

Hübel, K ;

Staib, P ;

Schulz, A ;

Diehl, V ;

Engert, A .

ANNALS OF ONCOLOGY, 2001, 12 (05) :661-667

[7] A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly [J].

Dawson, LK ;

Jodrell, DI ;

Bowman, A ;

Rye, R ;

Byrne, B ;

Bernareggi, A ;

Camboni, G .

EUROPEAN JOURNAL OF CANCER, 2000, 36 (18) :2353-2359

[8] LARGE-SCALE PREPARATION OF MYELIN BASIC PROTEIN FROM CENTRAL NERVOUS-TISSUE OF SEVERAL MAMMALIAN SPECIES [J].

DEIBLER, GE ;

KIES, MW ;

MARTENSON, RE .

PREPARATIVE BIOCHEMISTRY, 1972, 2 (02) :139-+

[9]

Dubois B, 2001, MULT SCLER S1, V7, pS20

[10]

Edan G, 2002, NEUROLOGY, V58, pA168

← 1 2 3 →